Potential and emerging treatment options for Ebola virus disease (Q38270149)

1 September 2017

1 reference

title

Potential and emerging treatment options for Ebola virus disease (English)

1 reference

1 September 2017

main subject

Ebola hemorrhagic fever

0 references

Orthoebolavirus zairense

0 references

author name string

Bryan M Bishop

series ordinal

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

20 November 2014

1 reference

Annals of Pharmacotherapy

1 September 2017

published in

1 reference

1 September 2017

volume

49

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

196-206

1 reference

Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Pathogenesis of viral hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

US signs contract with ZMapp maker to accelerate development of the Ebola drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

First Ebola treatment is approved by WHO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Ebola: a call for blood transfusion strategy in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Persistent immune responses after Ebola virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Development of CMX001 for the Treatment of Poxvirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

FDA allows second experimental drug to be tested in Ebola patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

On chikungunya acute infection and chloroquine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

A new player in the puzzle of filovirus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Anticoagulant effects of statins and their clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

A practical treatment for patients with Ebola virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Effect of the use of low and high potency statins and sepsis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Lovastatin for adult patients with dengue: protocol for a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Ebola vaccine--an urgent international priority

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Experimental Ebola drugs enter the limelight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Effective post-exposure treatment of Ebola infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Caring for critically ill patients with ebola virus disease. Perspectives from West Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Clinical management of filovirus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

21 January 2018

Ebola haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014561227

21 January 2018

Identifiers

DOI

10.1177/1060028014561227

1 reference

1 September 2017

1 reference